This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2011 Apr 20;103(8):616-7.

doi: 10.1093/jnci/djr104. Epub 2011 Mar 21.

Accelerated approval of oncology drugs: can we do better?

Susan S Ellenberg

PMID: 21422401
DOI: 10.1093/jnci/djr104

Editorial

Accelerated approval of oncology drugs: can we do better?

Susan S Ellenberg. J Natl Cancer Inst. 2011.

. 2011 Apr 20;103(8):616-7.

doi: 10.1093/jnci/djr104. Epub 2011 Mar 21.

Author

Susan S Ellenberg

PMID: 21422401
DOI: 10.1093/jnci/djr104

No abstract available

PubMed Disclaimer

Comment on

Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Johnson JR, et al. J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21. J Natl Cancer Inst. 2011. PMID: 21422403 Review.

Similar articles

Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Johnson JR, et al. J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21. J Natl Cancer Inst. 2011. PMID: 21422403 Review.
Accelerated approval of oncology products: a decade of experience.
Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Dagher R, et al. J Natl Cancer Inst. 2004 Oct 20;96(20):1500-9. doi: 10.1093/jnci/djh279. J Natl Cancer Inst. 2004. PMID: 15494600 Review.
Accelerated approval and oncology drug development timelines.
Lanthier ML, Sridhara R, Johnson JR, Farrell A, Keegan P, Justice R, Pazdur R. Lanthier ML, et al. J Clin Oncol. 2010 May 10;28(14):e226-7; author reply e228. doi: 10.1200/JCO.2009.26.2121. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194846 No abstract available.
Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
Schilsky RL. Schilsky RL. J Clin Oncol. 2003 Oct 15;21(20):3718-20. doi: 10.1200/JCO.2003.07.942. Epub 2003 Sep 8. J Clin Oncol. 2003. PMID: 12963701 No abstract available.
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
McKee AE, Farrell AT, Pazdur R, Woodcock J. McKee AE, et al. Oncologist. 2010;15 Suppl 1:13-8. doi: 10.1634/theoncologist.2010-S1-13. Oncologist. 2010. PMID: 20237212

See all similar articles

Cited by

Seattle Genetics rare cancer drug sails through accelerated approval.
DeFrancesco L. DeFrancesco L. Nat Biotechnol. 2011 Oct 13;29(10):851-2. doi: 10.1038/nbt1011-851. Nat Biotechnol. 2011. PMID: 21997610 No abstract available.
When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt.
Djulbegovic B, Hozo I. Djulbegovic B, et al. BMC Med Res Methodol. 2012 Jun 22;12:85. doi: 10.1186/1471-2288-12-85. BMC Med Res Methodol. 2012. PMID: 22726276 Free PMC article.
Time-dependent endpoints as predictors of overall survival in multiple myeloma.
Félix J, Aragão F, Almeida JM, Calado FJ, Ferreira D, Parreira AB, Rodrigues R, Rijo JF. Félix J, et al. BMC Cancer. 2013 Mar 16;13:122. doi: 10.1186/1471-2407-13-122. BMC Cancer. 2013. PMID: 23497363 Free PMC article.
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.
McPhail M, Weiss E, Bubela T. McPhail M, et al. Front Med (Lausanne). 2022 Feb 3;8:818647. doi: 10.3389/fmed.2021.818647. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35186979 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems